RxDoctor Payments DataLook up a doctor →

Gabriel Pardo, MD

Neurology · Oklahoma City, OKNPI 1215969605

Payments from drug & device makers

$10,252,343in general payments, 2019–2025

Across 2,287 payments — averaging $4482.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$4.3M
  • EMD Serono, Inc.$1M
  • AbbVie$938K
  • Genentech, Inc.$852K
  • Biogen$757K
  • TG Therapeutics, Inc.$738K
  • plus $1.6M from 37 others
$42,152in research payments, 2019–2025

Across 32 payments — averaging $1317.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$37K
  • Novartis$3K
  • Sanofi$2K

What the payments were for

  • Consulting fees$410,13128%
  • Speaking & faculty fees$857,07559%
  • Grants$2,2500%
  • Travel & lodging$123,6569%
  • Food & beverage$42,0903%
  • Education$13,2211%
  • Charitable contribution$4,0000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis229$4,334,400
EMD Serono, Inc.472$1,027,887
AbbVie(2 entities)87$937,587
Genentech, Inc.152$852,479
Biogen140$756,890
TG Therapeutics, Inc.233$738,454
Sanofi200$462,380
F. Hoffmann-la Roche AG110$369,122
Genentech USA, Inc.208$267,907
Amgen(2 entities)103$93,345
Roche Products Limited40$82,881
Ares Trading SA14$64,068
Bristol Myers Squibb71$55,991
Adamas Pharmaceuticals, Inc.38$51,315
E.r. Squibb & Sons, L.L.C.21$48,961
Hoffmann-la Roche Limited13$26,163
Alkermes, Inc.19$25,352
Modernatx, Inc.5$15,934
Johnson & Johnson10$10,685
AstraZeneca29$10,454
Merck Kgaa2$7,560
Merck Healthcare Kgaa1$6,300
Greenwich Biosciences, Inc.1$2,706
Cycle Pharmaceuticals Inc1$1,300
Cello Health Advantage Inc1$400
ANI Pharmaceuticals, Inc.13$363
Mallinckrodt Enterprises LLC13$318
Teva Pharmaceuticals USA, Inc.11$205
Supernus Pharmaceuticals, Inc.13$172
Avanir Pharmaceuticals, Inc.8$146
Amneal Pharmaceuticals LLC4$84
Vanda Pharmaceuticals Inc.3$71
Pfizer4$67
Coloplast3$59
Merz Pharmaceuticals, LLC2$54
Medtronic(2 entities)2$54
Saol Therapeutics Inc.2$52
Banner Life Sciences, LLC2$47
Axsome Therapeutics, Inc.2$37
Otsuka America Pharmaceutical, Inc.2$35
Piramal Critical Care1$24
Mallinckrodt Hospital Products Inc.1$17
Lilly USA, LLC1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,252,343 in reported general payments places this provider in the 95th percentile of 152 neurology providers in Oklahoma.

See all neurology providers in Oklahoma →

Medicare billing

Part B allowed, 2024
$1,497,197
Medicare patients
169
Services billed
28,405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EnspryngSatralizumab-Mwge23$719,956
CopaxoneGlatiramer Acetate92$542,621
MayzentSiponimod44$493,776
AubagioTeriflunomide38$450,702
Kesimpta PenOfatumumab38$365,926
Avonex Pen (4 Pack)Interferon Beta-1a30$258,535
Dimethyl Fumarate14$91,473
FingolimodFingolimod Hcl23$69,888
NuedextaDextromethorphan Hbr/Quinidine40$63,914
Teriflunomide83$61,317
GlatopaGlatiramer Acetate15$58,947
Glatiramer Acetate21$56,412
Dalfampridine ErDalfampridine54$45,912
MyrbetriqMirabegron49$36,593
Aimovig AutoinjectorErenumab-Aooe12$8,572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech USA, Inc.Enspryng$267,907$719,95623 claims
Teva Pharmaceuticals USA, Inc.Copaxone$205$542,62192 claims
NovartisMayzent$4,334,400$493,77644 claims
SanofiAubagio$462,380$450,70238 claims
Avanir Pharmaceuticals, Inc.Nuedexta$146$63,91440 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$84$89714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 152 neurology providers in Oklahoma.

Other neurology in Oklahoma City

See the full list for Oklahoma →

Where these figures come from

Is this you, or does something look wrong? →